Ramping up remdesivir supply, Gilead gifts 1.5 million doses for COVID-19

6 April 2020

Gilead Sciences (Nasdaq: GILD) chief executive Daniel O'Day has published an open letter providing an update on his firm’s work to develop remdesivir for people with COVID-19.

Shares in the company have bucked the bearish market trend in recent weeks, after early indications suggested the investigational agent, developed initially for Ebola, could be used to treat symptoms of the novel coronavirus outbreak.

With the help of regulators, Gilead has rapidly kicked off trials in multiple jurisdictions in an attempt to gather evidence of its effectiveness.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK